The 2022 focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension

키워드

참고문헌 (186)

1. Kallioinen N, "Sources of inaccuracy in the measurement of adult patients’ resting blood pressure in clinical settings : a systematic review", J Hypertens, 35, pp.421~441 (2017)
2. Stergiou GS, "2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement", J Hypertens, 39, pp.1293~1302 (2021)
3. "Hypertension:management of hypertension in adults in primary care" (2006)[URL]
4. "Mercury sphygmomanometers in healthcare and the feasibility of alternatives" (2009)[URL]
5. Clark CE, "Association of a difference in systolic blood pressure between arms with vascular disease and mortality : a systematic review and meta-analysis", Lancet, 379, pp.905~914 (2012)
6. Sheppard JP, "Blood Pressure Measurement Working Party of the British and Irish Hypertension Society. Measurement of blood pressure in the leg: a statement on behalf of the British and Irish Hypertension Society", J Hum Hypertens, 34, pp.418~419 (2020)
7. Chobanian AV, "Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure", Hypertension, 42, pp.1206~1252 (2003)
8. Cooke G, "Is pulse palpation helpful in detecting atrial fibrillation? : a systematic review", J Fam Pract, 55, pp.130~134 (2006)
9. Julius S, "Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension", Am J Cardiol, 109, pp.685~692 (2012)
10. Pickering TG, "Ambulatory blood-pressure monitoring", N Engl J Med, 354, pp.2368~2374 (2006)
11. O’Brien E, "European Society of Hypertension position paper on ambulatory blood pressure monitoring", J Hypertens, 31, pp.1731~1768 (2013)
12. Kario K, "Expert panel consensus recommendations for ambulatory blood pressure monitoring in Asia : the HOPE Asia network", J Clin Hypertens(Greenwich), 21, pp.1250~1283 (2019)
13. Stergiou GS, "Home blood pressure monitoring in the diagnosis and treatment of hypertension : a systematic review", Am J Hypertens, 24, pp.123~134 (2011)
14. Whelton PK, "2017 ACC", AHA, ABC, pp.ACPM, AGS[DOI]
15. Park S, "Expert panel consensus recommendations for home blood pressure monitoring in Asia : the Hope Asia network", J Hum Hypertens, 32, pp.249~258 (2018)
16. Staessen JA, "Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators", JAMA, 282, pp.539~546 (1999)
17. Dolan E, "Superiority of ambulatory over clinic blood pressure measurement in predicting mortality : the Dublin outcome study", Hypertension, 46, pp.156~161 (2005)
18. Ohkubo T, "Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement : a population-based observation in Ohasama, Japan", J Hypertens, 16, pp.971~975 (1998)
19. Niiranen TJ, "Home-measured blood pressure is a stronger predictor of cardiovascular risk than office blood pressure : the Finn-home study", Hypertension, 55, pp.1346~1351 (2010)
20. Ohkubo T, "Prognosis of"masked"hypertension and"white-coat"hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study", J Am Coll Cardiol, 46, pp.508~515 (2005)
21. Pierdomenico SD, "Prognostic value of masked uncontrolled hypertension", Hypertension, 72, pp.862~869 (2018)
22. Omboni S, "Reproducibility and clinical value of nocturnal hypotension : prospective evidence from the SAMPLE study : Study on Ambulatory Monitoring of Pressure and Lisinopril Evaluation", J Hypertens, 16, pp.733~738 (1998)
23. Verdecchia P, "Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension", Circulation, 81, pp.528~536 (1990)
24. Pierdomenico SD, "Circadian blood pressure changes and myocardial ischemia in hypertensive patients with coronary artery disease", J Am Coll Cardiol, 31, pp.1627~1634 (1998)
25. Ohkubo T, "Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure : the Ohasama study", J Hypertens, 20, pp.2183~2189 (2002)
26. Milazzo V, "Reverse blood pressure dipping as marker of dysautonomia in Parkinson disease", Parkinsonism Relat Disord, 56, pp.82~87 (2018)
27. Hamada T, "The clinical significance of abnormal diurnal blood pressure variation in healthy late middle-aged and older adults", Blood Press, 17, pp.134~140 (2008)
28. 김배근, "A Reverse Dipping Pattern Predicts Cardiovascular Mortality In a Clinical Cohort", Journal of Korean Medical Science, 28(10), pp.1468~1473 (2013), 대한의학회
29. Kario K, "Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives : a prospective study", Circulation, 107, pp.1401~1406 (2003)
30. Kario K, "Morning surge in blood pressure and cardiovascular risk : evidence and perspectives", Hypertension, 56, pp.765~773 (2010)
31. Tucker KL, "Self-monitoring of blood pressure in hypertension : a systematic review and individual patient data meta-analysis", PLoS Med, 14, pp.e1002389~ (2017)
32. Brady TM, "Effects of different rest period durations prior to blood pressure measurement : the best rest trial", Hypertension, 78, pp.1511~1519 (2021)
33. Verberk WJ, "Self-measurement of blood pressure at home reduces the need for antihypertensive drugs : a randomized, controlled trial", Hypertension, 50, pp.1019~1025 (2007)
34. Agarwal R, "Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control : a systematic review and meta-analysis", Hypertension, 57, pp.29~38 (2011)
35. McManus RJ, "Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication(TASMINH4) : an unmasked randomised controlled trial", Lancet, 391, pp.949~959 (2018)
36. Arrieta A, "Cost-benefit analysis of home blood pressure monitoring in hypertension diagnosis and treatment : an insurer perspective", Hypertension, 64, pp.891~896 (2014)
37. The Korean Society of Hypertension, "Guidelines for home blood pressure management", The Korean Society of Hypertension, ~ (2011)
38. Mancia G, "Long-term risk of sustained hypertension in white-coat or masked hypertension", Hypertension, 54, pp.226~232 (2009)
39. Faria J, "Long-term risk of progression to sustained hypertension in white-coat hypertension with normal night-time blood pressure values", Int J Hypertens, 2020, pp.8817544~ (2020)
40. Banegas JR, "Effectiveness of blood pressure control outside the medical setting", Hypertension, 49, pp.62~68 (2007)
41. de la Sierra A, "Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring", Hypertension, 57, pp.898~902 (2011)
42. Pickering TG, "How common is white coat hypertension?", JAMA, 259, pp.225~228 (1988)
43. Pickering TG, "Masked hypertension", Hypertension, 40, pp.795~796 (2002)
44. Vinyoles E, "Clinical characteristics of isolated clinic hypertension", J Hypertens, 26, pp.438~445 (2008)
45. 신진호, "Discordance between ambulatory versus clinic blood pressure according to global cardiovascular risk group", The Korean Journal of Internal Medicine, 30(5), pp.610~619 (2015), 대한내과학회[DOI]
46. 황의석, "Prevalence, Predictive Factor and Clinical Significance of White-Coat Hypertension and Masked Hypertension in Korean Hypertensive patients", The Korean Journal of Internal Medicine, 22(4), pp.256~262 (2007), 대한내과학회
47. Verdecchia P, "Independent predictors of isolated clinic(‘white-coat’)hypertension", J Hypertens, 19, pp.1015~1020 (2001)
48. Obara T, "Isolated uncontrolled hypertension at home and in the office among treated hypertensive patients from the J-HOME study", J Hypertens, 23, pp.1653~1660 (2005)
49. Verdecchia P, "Short-and long-term incidence of stroke in white-coat hypertension", Hypertension, 45, pp.203~208 (2005)
50. Banegas JR, "High prevalence of masked uncontrolled hypertension in people with treated hypertension", Eur Heart J, 35, pp.3304~3312 (2014)
51. Verdecchia P, "Prognostic significance of the white coat effect", Hypertension, 29, pp.1218~1224 (1997)
52. Verberk WJ, "Prevalence, causes, and consequences of masked hypertension : a meta-analysis", Am J Hypertens, 21, pp.969~975 (2008)
53. Björklund K, "Isolated ambulatory hypertension predicts cardiovascular morbidity in elderly men", Circulation, 107, pp.1297~1302 (2003)
54. Hyun-Jin Kim, "Clinical features and predictors of masked uncontrolled hypertension from the Korean Ambulatory Blood Pressure Monitoring Registry", The Korean Journal of Internal Medicine, 36(5), pp.1102~1114 (2021), 대한내과학회[DOI]
55. Hänninen MR, "Determinants of masked hypertension in the general population : the Finn-home study", J Hypertens, 29, pp.1880~1888 (2011)
56. Asayama K, "Setting thresholds to varying blood pressure monitoring intervals differentially affects risk estimates associated with white-coat and masked hypertension in the population", Hypertension, 64, pp.935~942 (2014)
57. Viera AJ, "Reproducibility of masked hypertension among adults 30 years or older", Blood Press Monit, 19, pp.208~215 (2014)
58. SPRINT Research Group, "A randomized trial of intensive versus standard bloodpressure control", N Engl J Med, 373, pp.2103~2116 (2015)
59. Myers MG, "Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension : randomised parallel design controlled trial", BMJ, 342, pp.d286~ (2011)
60. Myers MG, "The conventional versus automated measurement of blood pressure in the office(CAMBO)trial : masked hypertension sub-study", J Hypertens, 30, pp.1937~1941 (2012)
61. Wohlfahrt P, "Threshold for diagnosing hypertension by automated office blood pressure using random sample population data", J Hypertens, 34, pp.2180~2186 (2016)
62. Myers MG, "Office blood pressure is lower than awake ambulatory blood pressure at lower targets for treatment", J Clin Hypertens(Greenwich), 19, pp.1210~1213 (2017)
63. 이해영, "Smartphone", smartwatch-based cuffless blood pressure measurement : a position paper from the Korean Society of Hypertension, 2021, pp.27(2), 37~44[DOI]
64. McEniery CM, "Central blood pressure : current evidence and clinical importance", Eur Heart J, 35, pp.1719~1725 (2014)
65. Roman MJ, "Central pressure more strongly relates to vascular disease and outcome than does brachial pressure : the Strong Heart Study", Hypertension, 50, pp.197~203 (2007)
66. Flint AC, "Effect of systolic and diastolic blood pressure on cardiovascular outcomes", N Engl J Med, 381, pp.243~251 (2019)
67. Lewington S, "Age-specific relevance of usual blood pressure to vascular mortality : a meta-analysis of individual data for one million adults in 61 prospective studies", Lancet, 360, pp.1903~1913 (2002)
68. US Preventive Services Task Force, "Screening for hypertension in adults : US preventive services task force reaffirmation recommendation statement", JAMA, 325, pp.1650~1656 (2021)
69. James PA, "2014 evidence-based guideline for the management of high blood pressure in adults : report from the panel members appointed to the Eighth Joint National Committee(JNC 8)", JAMA, 311, pp.507~520 (2014)
70. Guirguis-Blake JM, "Screening for hypertension in adults : updated evidence report and systematic review for the US preventive services task force", JAMA, 325, pp.1657~1669 (2021)
71. Kaczorowski J, "Improving cardiovascular health at population level : 39 community cluster randomised trial of cardiovascular health awareness program(CHAP)", BMJ, 342, pp.d442~ (2011)
72. Mann AH, "The psychological effect of a screening programme and clinical trial for hypertension upon the participants", Psychol Med, 7, pp.431~438 (1977)
73. Ameling EH, "Impact of diagnosis and treatment of hypertension on quality of life : a double-blind, randomized, placebo-controlled, cross-over study of betaxolol", J Cardiovasc Pharmacol, 18, pp.752~760 (1991)
74. Tompson AC, "Acceptability and psychological impact of out-ofoffice monitoring to diagnose hypertension : an evaluation of survey data from primary care patients", Br J Gen Pract, 69, pp.e389~97 (2019)
75. Verdecchia P, "Ambulatory blood pressure and cardiovascular outcome in relation to perceived sleep deprivation", Hypertension, 49, pp.777~783 (2007)
76. Viera AJ, "Tolerability of the Oscar 2ambulatory blood pressure monitor among research participants : a cross-sectional repeated measures study", BMC Med Res Methodol, 11, pp.59~ (2011)
77. Sherwood A, "The effects of ambulatory blood pressure monitoring on sleep quality in men and women with hypertension: dipper vs. nondipper and race differences", Am J Hypertens, 32, pp.54~60 (2019)
78. Visseren FL, "2021 ESC guidelines on cardiovascular disease prevention in clinical practice", Eur Heart J, 42, pp.3227~3337 (2021)
79. Stevens LA, "Assessing kidney function : measured and estimated glomerular filtration rate", N Engl J Med, 354, pp.2473~2483 (2006)
80. Dharnidharka VR, "Serum cystatin C is superior to serum creatinine as a marker of kidney function : a meta-analysis", Am J Kidney Dis, 40, pp.221~226 (2002)
81. Inker LA, "Estimating glomerular filtration rate from serum creatinine and cystatin C", N Engl J Med, 367, pp.20~29 (2012)
82. Kilbride HS, "Accuracy of the MDRD(Modification of Diet in Renal Disease)study and CKD-EPI(CKD epidemiology collaboration)equations for estimation of GFR in the elderly", Am J Kidney Dis, 61, pp.57~66 (2013)
83. 2013 KDIGO, "Chapter 1 : definition and classification of CKD", Kidney Int Suppl (2011), 3, pp.19~62 (2013)
84. Johnson DW, "Chronic kidney disease and automatic reporting of estimated glomerular filtration rate : new developments and revised recommendations", Med J Aust, 197, pp.224~225 (2012)
85. Zanchetti A, "When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal", J Hypertens, 27, pp.923~934 (2009)
86. Sundström J, "Effects of blood pressure reduction in mild hypertension : a systematic review and meta-analysis", Ann Intern Med, 162, pp.184~191 (2015)
87. Law MR, "Use of blood pressure lowering drugs in the prevention of cardiovascular disease : meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies", BMJ, 338, pp.b1665~ (2009)
88. Lonn EM, "Bloodpressure lowering in intermediate-risk persons without cardiovascular disease", N Engl J Med, 374, pp.2009~2020 (2016)
89. Xie X, "Effects of intensive blood pressure lowering on cardiovascular and renal outcomes : updated systematic review and meta-analysis", Lancet, 387, pp.435~443 (2016)
90. Thomopoulos C, "Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels: updated overview and meta-analyses of randomized trials", J Hypertens, 34, pp.613~622 (2016)
91. Liu L, "The Felodipine Event Reduction(FEVER)study : a randomized long-term placebocontrolled trial in Chinese hypertensive patients", J Hypertens, 23, pp.2157~2172 (2005)
92. Zhang Y, "Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial", Eur Heart J, 32, pp.1500~1508 (2011)
93. Antithrombotic Trialists’(ATT)Collaboration, "Aspirin in the primary and secondary prevention of vascular disease : collaborative meta-analysis of individual participant data from randomised trials", Lancet, 373, pp.1849~1860 (2009)
94. Arnett DK, "2019 ACC", AHA guideline on the primary prevention of cardiovascular disease : a report of the American College of Cardiology, Circulation, pp.2019, 140[DOI]
95. US Preventive Services Task Force, "Aspirin use to prevent cardiovascular disease : US preventive services task force recommendation statement", JAMA, 327, pp.1577~1584 (2022)
96. Williams B, "2018 ESC", ESH guidelines for the management of arterial hypertension, 2018, pp.39, 3021~3104
97. Ridker PM, "Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein", N Engl J Med, 359, pp.2195~2207 (2008)
98. Yusuf S, "Cholesterol lowering in intermediate-risk persons without cardiovascular disease", N Engl J Med, 374, pp.2021~2031 (2016)
99. Cholesterol Treatment Trialists’(CTT)Collaboration, "Efficacy and safety of more intensive lowering of LDL cholesterol : a meta-analysis of data from 170, 000 participants in 26 randomised trials", Lancet, 376, pp.1670~1681 (2010)
100. 허규연, "2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association", Diabetes and Metabolism Journal, 45(4), pp.461~481 (2021), 대한당뇨병학회[DOI]
101. Kario K, "24-hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension : results from the randomized, placebo-controlled SACRA study", Circulation, 139, pp.2089~2097 (2018)
102. Ye N, "Blood pressure effects of canagliflozin and clinical outcomes in type 2diabetes and chronic kidney disease : insights from the CREDENCE trial", Circulation, 143, pp.1735~1749 (2021)
103. Bosworth HB, "Home blood pressure management and improved blood pressure control : results from a randomized controlled trial", Arch Intern Med, 171, pp.1173~1180 (2011)
104. Margolis KL, "Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control : a cluster randomized clinical trial", JAMA, 310, pp.46~56 (2013)
105. Ambrosius WT, "The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure : the Systolic Blood Pressure Intervention Trial(SPRINT)", Clin Trials, 11, pp.532~546 (2014)
106. Xu W, "Optimal systolic blood pressure target, time to intensification, and time to follow-up in treatment of hypertension : population based retrospective cohort study", BMJ, 350, pp.h158~ (2015)
107. Birtwhistle RV, "Randomised equivalence trial comparing three month and six month follow up of patients with hypertension by family practitioners", BMJ, 328, pp.204~ (2004)
108. Iskedjian M, "Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy : evidence from a meta-analysis", Clin Ther, 24, pp.302~316 (2002)
109. Schroeder K, "How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials", Arch Intern Med, 164, pp.722~732 (2004)
110. Bangalore S, "Fixed-dose combinations improve medication compliance : a meta-analysis", Am J Med, 120, pp.713~719 (2007)
111. Gupta AK, "Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents : a meta-analysis", Hypertension, 55, pp.399~407 (2010)
112. Roshandel G, "Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases(PolyIran) : a pragmatic, cluster-randomised trial", Lancet, 394, pp.672~683 (2019)
113. Tung YC, "Medication compliance and clinical outcomes of fixed-dose combinations vs free combinations of an angiotensin II receptor blocker and a calcium channel blocker in hypertension treatment", J Clin Hypertens(Greenwich), 19, pp.983~989 (2017)
114. Ibanez B, "2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation : the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology(ESC)", Eur Heart J, 39, pp.119~177 (2018)
115. ACCORD Study Group, "Effects of intensive blood-pressure control in type 2diabetes mellitus", N Engl J Med, 362, pp.1575~1585 (2010)
116. Patel A, "Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus(the ADVANCE trial) : a randomised controlled trial", Lancet, 370, pp.829~840 (2007)
117. Emdin CA, "Blood pressure lowering in type 2 diabetes : a systematic review and meta-analysis", JAMA, 313, pp.603~615 (2015)
118. Brunström M, "Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus : systematic review and meta-analyses", BMJ, 352, pp.i717~ (2016)
119. Zhang W, "Trial of intensive blood-pressure control in older patients with hypertension", N Engl J Med, 385, pp.1268~1279 (2021)
120. Buckley LF, "Intensive versus standard blood pressure control in SPRINTeligible participants of ACCORD-BP", Diabetes Care, 40, pp.1733~1738 (2017)
121. Turnbull F, "Effects of different blood-pressure-lowering regimens on major cardiovascular events : results of prospectively-designed overviews of randomised trials", Lancet, 362, pp.1527~1535 (2003)
122. Lindholm LH, "Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study(LIFE) : a randomised trial against atenolol", Lancet, 359, pp.1004~1010 (2002)
123. Berl T, "Cardiovascular outcomes in the Irbesartan diabetic nephropathy trial of patients with type 2 diabetes and overt nephropathy", Ann Intern Med, 138, pp.542~549 (2003)
124. Palmer SC, "Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease : a network meta-analysis", Lancet, 385, pp.2047~2056 (2015)
125. Weber MA, "Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy : a randomised, double-blind, placebo-controlled, phase 3study", Lancet Diabetes Endocrinol, 4, pp.211~220 (2016)
126. Juraschek SP, "Effects of intensive blood pressure treatment on orthostatic hypotension : a systematic review and individual participant-based meta-analysis", Ann Intern Med, 174, pp.58~68 (2021)
127. Freeman R, "Orthostatic hypotension : JACC state-of-the-art review", J Am Coll Cardiol, 72, pp.1294~1309 (2018)
128. Bundy JD, "Systolic blood pressure reduction and risk of cardiovascular disease and mortality : a systematic review and network meta-analysis", JAMA Cardiol, 2, pp.775~781 (2017)
129. Leenen FH, "Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial", Hypertension, 48, pp.374~384 (2006)
130. Zanchetti A, "Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine : an analysis of findings from the VALUE trial", J Hypertens, 24, pp.2163~2168 (2006)
131. Böhm M, "Achieved blood pressure and cardiovascular outcomes in high-risk patients : results from ONTARGET and TRANSCEND trials", Lancet, 389, pp.2226~2237 (2017)
132. Borghi C, "Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long-Term Evaluation", Am J Hypertens, 12, pp.665~672 (1999)
133. Fox KM, "EURopean trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)", Lancet, 362, pp.782~788 (2003)
134. Healey JS, "Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers : a meta-analysis", J Am Coll Cardiol, 45, pp.1832~1839 (2005)
135. Zhao D, "Prevention of atrial fibrillation with renin-angiotensin system inhibitors on essential hypertensive patients : a meta-analysis of randomized controlled trials", J Biomed Res, 29, pp.475~485 (2015)
136. Kirchhof P, "Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET", EHRA consensus conference, 2011, pp.106, 1012~1019
137. 이기홍, "2021 대한부정맥학회 심방세동 환자의 뇌졸중 예방 관리 지침", 대한내과학회지, 96(4), pp.296~311 (2021), 대한내과학회[DOI]
138. Nakamura K, "Treatment of hypertension in coarctation of the aorta", Curr Treat Options Cardiovasc Med, 18, pp.40~ (2016)
139. Schaefer BM, "The bicuspid aortic valve : an integrated phenotypic classification of leaflet morphology and aortic root shape", Heart, 94, pp.1634~1638 (2008)
140. Davies RR, "Natural history of ascending aortic aneurysms in the setting of an unreplaced bicuspid aortic valve", Ann Thorac Surg, 83, pp.1338~1344 (2007)
141. Lindman BR, "Time to treat hypertension in patients with aortic stenosis", Circulation, 128, pp.1281~1283 (2013)
142. Upadhyay A, "Systematic review : blood pressure target in chronic kidney disease and proteinuria as an effect modifier", Ann Intern Med, 154, pp.541~548 (2011)
143. Arguedas JA, "Treatment blood pressure targets for hypertension", Cochrane Database Syst Rev, 3, pp.CD004349~ (2009)
144. Mancia G, "2013 ESH", ESC guidelines for the management of arterial hypertension : the task force for the management of arterial hypertension of the European Society of Hypertension(ESH)and of the European Society of Cardiology(ESC), 2013, pp.31, 1281~1357
145. Appel LJ, "Intensive blood-pressure control in hypertensive chronic kidney disease", N Engl J Med, 363, pp.918~929 (2010)
146. Fried LF, "Combined angiotensin inhibition for the treatment of diabetic nephropathy", N Engl J Med, 369, pp.1892~1903 (2013)
147. Xie X, "Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD : a Bayesian network meta-analysis of randomized clinical trials", Am J Kidney Dis, 67, pp.728~741 (2016)
148. Kidney Disease : Improving Global Outcomes(KDIGO)Blood Pressure Work Group, "KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease", Kidney Int, 99(3S), pp.S1~87 (2021)
149. Parving HH, "Cardiorenal end points in a trial of aliskiren for type 2diabetes", N Engl J Med, 367, pp.2204~2213 (2012)
150. Cheung AK, "Effects of intensive BP control in CKD", J Am Soc Nephrol, 28, pp.2812~2823 (2017)
151. Tomson CR, "Management of blood pressure in patients with chronic kidney disease not receiving dialysis : synopsis of the 2021 KDIGO clinical practice guideline", Ann Intern Med, 174, pp.1270~1281 (2021)
152. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, "Tissue plasminogen activator for acute ischemic stroke", N Engl J Med, 333, pp.1581~1587 (1995)
153. Hacke W, "Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke", N Engl J Med, 359, pp.1317~1329 (2008)
154. Berkhemer OA, "A randomized trial of intraarterial treatment for acute ischemic stroke", N Engl J Med, 372, pp.11~20 (2015)
155. Goyal M, "Randomized assessment of rapid endovascular treatment of ischemic stroke", N Engl J Med, 372, pp.1019~1030 (2015)
156. Saver JL, "Stentretriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke", N Engl J Med, 372, pp.2285~2295 (2015)
157. Campbell BC, "Endovascular therapy for ischemic stroke with perfusion-imaging selection", N Engl J Med, 372, pp.1009~1018 (2015)
158. Jovin TG, "Thrombectomy within 8 hours after symptom onset in ischemic stroke", N Engl J Med, 372, pp.2296~2306 (2015)
159. Bracard S, "Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke(THRACE) : a randomised controlled trial", Lancet Neurol, 15, pp.1138~1147 (2016)
160. Nogueira RG, "Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct", N Engl J Med, 378, pp.11~21 (2018)
161. Albers GW, "Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging", N Engl J Med, 378, pp.708~718 (2018)
162. Robinson TG, "Effects of antihypertensive treatment after acute stroke in the continue or stop post-stroke antihypertensives collaborative study(COSSACS) : a prospective, randomised, open, blinded-endpoint trial", Lancet Neurol, 9, pp.767~775 (2010)
163. He J, "Effects of immediate blood pressure reduction on death and major disability in patients with acute ischemic stroke : the CATIS randomized clinical trial", JAMA, 311, pp.479~489 (2014)
164. Sandset EC, "The angiotensin-receptor blocker candesartan for treatment of acute stroke(SCAST) : a randomised, placebo-controlled, double-blind trial", Lancet, 377, pp.741~750 (2011)
165. Anderson CS, "Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage", N Engl J Med, 368, pp.2355~2365 (2013)
166. Qureshi AI, "Intensive blood-pressure lowering in patients with acute cerebral hemorrhage", N Engl J Med, 375, pp.1033~1043 (2016)
167. Rodriguez-Luna D, "Impact of blood pressure changes and course on hematoma growth in acute intracerebral hemorrhage", Eur J Neurol, 20, pp.1277~1283 (2013)
168. Sakamoto Y, "Systolic blood pressure after intravenous antihypertensive treatment and clinical outcomes in hyperacute intracerebral hemorrhage : the stroke acute management with urgent risk-factor assessment and improvement-intracerebral hemorrhage study", Stroke, 44, pp.1846~1851 (2013)
169. Tsivgoulis G, "Intensive blood pressure reduction in acute intracerebral hemorrhage : a meta-analysis", Neurology, 83, pp.1523~1529 (2014)
170. Liu L, "Blood pressure reduction for the secondary prevention of stroke : a Chinese trial and a systematic review of the literature", Hypertens Res, 32, pp.1032~1040 (2009)
171. Lakhan SE, "Blood pressure lowering treatment for preventing stroke recurrence : a systematic review and meta-analysis", Int Arch Med, 2, pp.30~ (2009)
172. Arima H, "Effects of blood pressure lowering on intracranial and extracranial bleeding in patients on antithrombotic therapy : the PROGRESS trial", Stroke, 43, pp.1675~1677 (2012)
173. PROGRESS Collaborative Group, "Randomised trial of a perindoprilbased blood-pressure-lowering regimen among 6, 105 individuals with previous stroke or transient ischaemic attack", Lancet, 358, pp.1033~1041 (2001)
174. Ettehad D, "Blood pressure lowering for prevention of cardiovascular disease and death : a systematic review and meta-analysis", Lancet, 387, pp.957~967 (2016)
175. SPS3 Study Group, "Blood-pressure targets in patients with recent lacunar stroke : the SPS3 randomised trial", Lancet, 382, pp.507~515 (2013)
176. La Torre A, "Sexual dysfunction related to drugs: a critical review. Part IV: cardiovascular drugs", Pharmacopsychiatry, 48, pp.1~6 (2015)
177. Foy CG, "Blood pressure, sexual activity, and dysfunction in women with hypertension : baseline findings from the Systolic Blood Pressure Intervention Trial(SPRINT)", J Sex Med, 13, pp.1333~1346 (2016)
178. "Hypertension in adults: diagnosis and management" (2011)[URL]
179. Peters R, "Incident dementia and blood pressure lowering in the hypertension in the very elderly trial cognitive function assessment(HYVETCOG) : a double-blind, placebo controlled trial", Lancet Neurol, 7, pp.683~689 (2008)
180. Applegate WB, "Impact of the treatment of isolated systolic hypertension on behavioral variables : results from the systolic hypertension in the elderly program", Arch Intern Med, 154, pp.2154~2160 (1994)
181. Forette F, "Prevention of dementia in randomised double-blind placebocontrolled Systolic Hypertension in Europe(Syst-Eur)trial", Lancet, 352, pp.1347~1351 (1998)
182. Forette F, "The prevention of dementia with antihypertensive treatment : new evidence from the Systolic Hypertension in Europe(Syst-Eur)study", Arch Intern Med, 162, pp.2046~2052 (2002)
183. Tzourio C, "Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease", Arch Intern Med, 163, pp.1069~1075 (2003)
184. Lithell H, "The Study on Cognition and Prognosis in the Elderly(SCOPE) : principal results of a randomized double-blind intervention trial", J Hypertens, 21, pp.875~886 (2003)
185. Hughes D, "Association of blood pressure lowering with incident dementia or cognitive impairment : a systematic review and meta-analysis", JAMA, 323, pp.1934~1944 (2020)
186. SPRINT MIND Investigators for the SPRINT Research Group, "Effect of intensive vs standard blood pressure control on probable dementia : a randomized clinical trial", JAMA, 321, pp.553~561 (2019)

관련 논문AI추천